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ORIGINAL STUDYHigh Prevalence and Incidence of Asymptomatic
Sexually Transmitted Infections During Pregnancy
and Postdelivery in KwaZulu Natal, South Africa
Dhayendre Moodley, PhD,* Prashini Moodley, PhD,† Motshedisi Sebitloane, MD,*
Deepak Soowamber, BBusSci,‡ Heather Luz McNaughton-Reyes, PhD,§
Allison K. Groves, PhD,¶ and Suzanne Maman, PhD§Background: We report the prevalence and incidence of 3 treatable sex-
ually transmitted pathogens (Neiserria gonorrhoeae, Chlamydia trachomatis,
and Trichomonas vaginalis) in women who were HIV infected or at high
risk for HIV infection, in pregnancy and postpartum, respectively.
Method: Vulvovaginal specimens collected at the first antenatal visit and
again at 14 weeks postpartum were tested for N. gonorrhoeae, C. trachomatis,
and T. vaginalis in the laboratory. Women were routinely tested for HIV-1
with a point-of-care test.
Results: Among 1480 women, 32.3% (95% confidence interval, 29.9–34.7)
tested positive for any of the sexually transmitted infections (STIs) in preg-
nancy and 19.2% (95% confidence interval, 16.9–21.5) were positivewhen
retested 14 weeks postpartum (incidence rate, 79.2 per 100 person-years).
The prevalence of N. gonorrhoeae and T. vaginalis infections in preg-
nancy and the incidence rate of any STI at 14 weeks postpartum were sig-
nificantly higher in HIV-1–infected women (P < 0.0001 amd P = 0.0079).
More than 50% of N. gonorrhoeae, T. vaginalis, and C. trachomatis infec-
tions in pregnancy were asymptomatic.
Conclusions: The high prevalence of asymptomatic STIs in pregnancy is
compelling evidence that demands the development and validation of point-
of-care tests for STIs be expedited. In addition, the high incidence of STIs
3 months postpartum suggests that women in this study setting resume un-
protected sexual intercourse soon after delivery.
A recent World Health Organization report estimated that 500million adults between the ages of 15 and 49 years acquire
1 of 4 curable sexually transmitted bacterial infections (Neiserria
gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, and
Trichomonas vaginalis) each year.1 In 2008 alone, 93 million
new cases of these sexually transmitted infections (STIs) were re-
ported in Africa. Almost half the cases were reported in women,
with 4.3 million cases attributable to C. trachomatis, 9.6 million
to N. gonorrhoeae, 1.6 million to T. pallidum, and 28.1 million
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women to include spontaneous abortion, preterm labor, infection
in neonates, and pelvic inflammatory disease associated with ecto-
pic pregnancies and infertility.2,3
More importantly, with particular reference to populations
at high risk for HIV infection, an association between the classical
STIs and HIV has triggered the need for early detection and prompt
treatment of STIs.4,5 These cohort and laboratory-based studies,
together with hypothetical models, have demonstrated plausible
mechanisms of how the bacterial causes of STIs could facilitate
the receptive transmission of their viral counterpart viz. HIV.
Hypothetically, the immediate and complete treatment of
curable STIs detected in women could significantly reduce the risk
for HIV infection. The syndromic management of STIs based on
clinical, epidemiological, and microbiological evidence has been
touted as the most feasible and cost-effective approach to reducing
the prevalence of STIs and is strongly recommended by the World
Health Organization for use in resource-limited settings.6 This
multifaceted approach adopted in South Africa in 1995 includes
treatment of symptomatic infection in addition to risk reduction
counseling, contact tracing, and provision of condoms.7 However,
the syndromic management strategy is not without its limitations.
Several studies validating the symptom-based diagnostic approach
against laboratory diagnosis have already reported several missed
opportunities for treatment and control in the general adult
population.8,9 There are few studies that have described the burden
of STI disease in pregnancy, and only one other study has reported
the incidence of STIs in postpartum women.10
In a randomized controlled trial designed to evaluate an
HIV counseling intervention (SAHAPS study) conducted at a pri-
mary health care clinic in SouthAfrica, specific STIs and inconsistent
condom use in pregnancy and postdelivery served as biological
and behavioral markers for risk reduction respectively.11 The
primary analysis revealed no effect of enhanced counseling on
incident STIs.11
We report the prevalence of STIs in this cohort of pregnant
women and the incidence at 14 weeks postdelivery, with the as-
sumption that all STIs detected in pregnancy were treated and had
resolved before delivery. We further explore the association be-
tween these curable STIs and HIV and evaluate the validity of
syndromic management in the detection and prompt treatment of
the classical STIs at these critical time points.
METHODS
Between May 2008 and June 2010, antenatal attendees at
a primary health clinic in Durban, who consented to participate
in the SAHAPS study, were tested for HIV and the other STIs
(N. gonorrhoeae, C. trachomatis, and T. vaginalis) at the first an-
tenatal visit in pregnancy (baseline) and subsequently at 14 weeks
postpartum. Participant recruitment, eligibility criteria, randomi-
zation, and retention strategy are described in greater detail in15 43
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Moodley et al.the primary article.11 Briefly, for the purpose of this secondary
data analysis, we included 1480 pregnant women enrolled in the
SAHAPS study. To be eligible for enrollment in the SAHAPS
study, women had to have a primary intimate partner for the past
6 months.Procedures
Study nurses provided antenatal care to all study partici-
pants according to the South African Antenatal Care guidelines.12
The antenatal and 14week postpartum assessments included a col-
lection of a vulvovaginal specimen. During the collection of these
vulvovaginal specimens, nurses noted the presence or absence of
an abnormal vaginal discharge. In addition, the syndromic man-
agement protocol was applied, and women were asked if they
thought they had an abnormal vaginal discharge. The specimen
swabs were temporarily refrigerated at the clinic and transported
within 6 hours to the STI diagnostic laboratory in the Department
of Infection Control, University of KwaZulu-Natal.Detection of N. gonorrhoeae, C. trachomatis,
and T. vaginalis
The swabs were processed forN. gonorrhoeae,C. trachomatis,
and T. vaginalis using the BD Probetec ETAmplified DNAAssay
(Becton Dickinson, Sparks, MD) using Strand Displacement tech-
nology to detect N. gonorrhoeae, C. trachomatis, and an in-house
validated polymerase chain reaction assay using the primer set
SarR and SarF specific for T. vaginalis.13Detection of HIV-1
Serological testing for HIV-1 was performed at the clinic
using a point of care (POC) testing algorithm. At their first antena-
tal visit, women were provided HIV pretest counseling and tested
for HIV-1 according to the HIV testing algorithm used in the ante-
natal clinic. A participant provided a blood specimen from a finger
prick for a POCHIV test (Determine: Abbott Laboratories, Abbott
Park, IL). If a reactive result was obtained with the Determine
rapid HIV test, the participant's HIV status was confirmed with a
second POC test (Smart Check: World Diagnostic Inc, Miami
Lakes, FL). Women who tested negative at the baseline visit were
routinely retested at 34 to 36 weeks' gestation using the same test-
ing algorithm. Nurses conducted posttest counseling sessions with
women. Details of the content of posttest counseling are provided
in the primary article.11
In compliancewith the local syndromicmanagement proto-
col, women reporting or presenting with symptoms suggestive of a
sexually transmitted disease were initiated on treatment on the same
day. Results from the laboratory diagnosis were available within 2
to 3 weeks, and women who were asymptomatic but tested posi-
tive by laboratory diagnosis were contacted and asked to return
to the clinic at their earliest convenience for initiation of treatment.
Every effort was made to ensure initiation of treatment as soon
as possible.Statistical Analysis
The data specific for this secondary analysis were selec-
tively extracted from the “medical extraction form” database that
housed the details and results of all laboratory investigations, as
well as a single variable that described an infection as “symptom-
atic” or “asymptomatic” based on the presence of an abnormal
vaginal discharge, as observed by the examining nurse or a verbal44 Sexuall
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age of women with the STI and 95% confidence intervals (CIs)
were calculated for these percentages, using the formulas for cal-
culating CIs for proportions. P values were calculated using Fisher
exact test. Incidence rates, with 95% CIs, were calculated as the
number of new cases of STIs over the total number of patient
years at risk. Risk ratios were also calculated using a log-
binomial regression. All statistical analyses were done with
SAS 9.3 (SAS Institute Inc, Cary, NC).
The study was approved by the institutional review boards
of the University of KwaZulu-Natal and the University of North
Carolina at Chapel Hill. Awritten informed consent was obtained
from all women who participated in the main study.RESULTS
Sample Recruitment, Retention, and
Laboratory Diagnosis
A total of 1480 pregnant women who completed a baseline
assessment before being randomized to 1 of 2 study arms in the
SAHAPS study were included in this analysis. Data were missing
for 21 (1.4%) women whowere therefore excluded from the anal-
ysis at baseline. The number of women who tested for each of the
3 curable STIs in pregnancy and subsequently at the 14-week post-
partum visit is illustrated in Figure 1. At the primary outcome visit
(14 weeks postdelivery), 1183 (79.9%) women returned for follow-
up and laboratory results were available for 1124 women who tested
for N. gonorrhoeae, C. trachomatis, and T. vaginalis.Baseline Characteristics
As previously reported in the primary outcome article, the
average gestational age at booking was 24 weeks, 37% (554/1480)
were first-time pregnancies and 25.9% (384/1480) were living with
their partner.11 Inconsistent condom use was common, with 68.9%
(1020/1480) of participants at baseline reported having had sex
without a condom in the past 30 days and fewer women (14%) re-
ported inconsistent condom use at 14 weeks postdelivery. We did
not collect information on condom use during the different stages
of pregnancy or between the baseline assessment and delivery.Prevalence and Incidence of STIs in Pregnancy
and 14 Weeks Postdelivery
The percentage of pregnant women testing positive for an
STI excluding HIV was 32.3% (95% CI, 29.9–34.7) at baseline
and 19.2% (95%CI, 16.9–21.5) at 14weeks postdelivery.C. trachomatis
and T. vaginalis were the most common pathogens detected in
pregnancy: 17.8% and 15.3%, respectively. N. gonorrhoeae was
detected in 6.4% of the women (Table 1).
When women were tested again at 14 weeks postdelivery,
C. trachomatis and T. vaginalis remained the most commonly
detected pathogens but at a lower prevalence of 10.1% and 8.9%,
respectively. N. gonorrhoeae was detected in 2.9% of the women
postdelivery.
In total, among 1124 women tested at 14 weeks postde-
livery, there were 216 (19.2%) women with an STI at 14 weeks
postdelivery. The STI results for 1 woman among the 216 cases
were inconclusive in pregnancy and were not reported as new in-
fections at 14 weeks. Overall, there were 86 new STIs at 14 weeks
postdelivery, among 986 women who were uninfected at screening
in pregnancy, with an incidence rate of 43.8 per 100 person-years
(95% CI, 35.1–54.1; Table 2). Of 337 women who had an STI aty Transmitted Diseases • Volume 42, Number 1, January 2015
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Figure 1. Flow diagram illustrating the number of women tested for each of the STIs at baseline (pregnancy) and subsequently at
14 weeks postdelivery.
Undetected, Incident STIs in Peripartum Womenbaseline and retested at 14 weeks postdelivery, 129 (38.3 %) also
had a detectable STI at 14 weeks postdelivery (21% N. gonorrhoeae,
27% T. vaginalis, and 30% C. trachomatis). Given that all women
with an STI at baseline were treated during pregnancy, the 216 in-
fections detected at 14 weeks postdelivery among 1124 women
could also be considered as new infections; incidence rate 79.2
per 100 person-years (95% CI, 69.0–90.5).
Prevalence and Incidence of STI in Association
With HIV
A total of 571 of the 1480 pregnant women tested positive
for HIVat their first antenatal visit (HIV prevalence, 38.58%; 95%
CI, 36.10–41.12). Among 410 seronegativewomen, the overall in-
cidence rate of HIVat 14 weeks was 5.49/100 person-years (95%
CI, 2.01–11.95). In pregnancy, there were no differences in the
prevalence estimates of any STI stratified by HIV status; however,
the prevalences of gonorrhea (9.8% vs. 4.4%) and trichomoniasis
(22.6% vs. 10.5%) were significantly higher in the HIV-positive
women (P < 0.0001). Overall, the incidence rate of any STI at
14 weeks postdelivery was also significantly higher among women
who tested HIV positive in pregnancy (58.0 per 100 person-years
vs. 36.4 per 100 person-years; P = 0.0079). More specifically, the
incidence of gonorrhea and that of trichomoniasis were 5.5 times
and 1.8 times higher in the HIV-positivewomen, respectively (Table 3).TABLE 1. Prevalence of STIs at Baseline (Pregnancy) and the Percentag
STI
Baseline (n = 1480)
% (n/N) 95% CI
N. gonorrhoeae 6.4 (93/1459) 5.12
T. vaginalis 15.3 (223/1459) 13.46
C. trachomatis 17.8 (259/1459) 15.79
Any STI 32.2 (470/1459) 29.88
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Among the 470 women who tested positive for any of the
3 STIs, 206 (43.8%) were symptomatic and were treated syndromi-
cally (N. gonorrhoeae 47.3%, T. vaginalis 47.1%, andC. trachomatis
42.9%) Furthermore, only 26 (12%) of 216 women with an STI
postdelivery were symptomatic, although the specificity of the
syndromic approach was much higher postdelivery (specificity
96.9%, negative predictive value 82.2%) as compared with preg-
nancy (specificity 68.7%, negative predictive value 71.9%).DISCUSSION
In this data analysis of a cohort of 1480 women enrolled
in pregnancy at a primary health care clinic with an antenatal
HIV prevalence of 38%, 1 (32.3%) in 3 women tested positive
for at least one of the curable bacterial STIs (N. gonorrhoeae,
C. trachomatis, or T. vaginalis) at the first antenatal visit and 1
(19.2%) in 5 women tested positive at 14 weeks postdelivery.
Considering the limited number of STI cohort studies conducted
among pregnant women, this is the first report of incident STIs
detected within 3 months postpartum in a population with a high
HIV antenatal seroprevalence. In addition, more than 50% of
women with an STI in pregnancy and more than 80% with an
STI postdelivery were asymptomatic.e of STIs at 14 Weeks Postdelivery
Postdelivery (n = 1183)
% (n/N) 95% CI
7.63 2.9 (33/1124) 1.95 3.93
17.15 8.9 (100/1124) 7.23 10.56
19.71 10.1 (113/1124) 8.30 11.81
34.68 19.2 (216/1124) 16.91 21.52
15 45
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TABLE 2. Incidence of STIs at 14 Weeks Postdelivery in Women Who Were Uninfected in Pregnancy and in All Women Assuming
Complete Resolution of STIs Detected in Pregnancy
STI
Women Uninfected in Pregnancy All Women (Women Infected and Uninfected in Pregnancy)*
Incidence Rate (Per 100 Person-Years) 95% CI Incidence Rate (Per 100 Patient-Years) 95% CI
N. gonorrhoeae 7.2 (20/279) 4.4 11.1 11.1 (33/297) 7.65 15.60
T. vaginalis 22.9 (57/249) 17.3 29.6 34.7 (100/288) 28.22 42.18
C. trachomatis 22.9 (55/240) 17.3 29.8 39.4 (113/287) 32.49 47.40
Any STI 43.8 (86/196) 35.0 54.1 79.2 (216/273) 68.97 90.45
*Assuming 100% cure rate of STIs treated in pregnancy.
Moodley et al.The only empirical studies conducted among pregnant women
in South Africa have described lower prevalence estimates than
those reported in our study. Locally, in a small study of pregnant
women (n = 168), the prevalence of chlamydia and gonorrhea in
1994 was almost half of what is reported in the current study.14
Our prevalence estimate of STIs in pregnant women enrolled
between 2008 and 2010 was similar to that reported among HIV-
uninfected nonpregnant women with multiple partners between
2004 and 2006.15 In this study, Mlisana et al.15 reported T. vaginalis
as the single most common infection in 242 nonpregnant high-
risk HIV-uninfected women, whereas we reported C. trachomatis
in addition to T. vaginalis as the more common infections in
both HIV-infected and HIV-uninfected women during pregnancy
(n = 1456) and postdelivery (n = 1124). Of note, the antenatal
HIV seroprevalence in South Africa in 1994 was 7.6% and
subsequently increased exponentially to reach an epidemic plateau
in 2004 (29.5%).16 The temporal association between the increased
prevalence of HIV and STIs in pregnancy alone is an indication of
the high sexual behavioral risk that has been grossly understudied
in pregnancy and demands more attention in respect of HIV
prevention, risk reduction counseling, and management of STIs.
Our findings raise many concerns related to diagnosis, man-
agement, and prevention of STIs in women during and after preg-
nancy. Our most significant findings were the higher prevalence
of gonorrhea (9.6% vs. 4.4%) and trichomoniasis (22.9% vs.
6.5%) among HIV-positive women and the significantly higher
incidence rate of any STI at 14 weeks postdelivery among women
who tested HIV positive in pregnancy (59.8 per 100 person-years
vs. 37.2 per 100 person-years). More specifically, the incidences
of gonorrhea and trichomoniasis were 5.6 times and 1.9 times
higher in the HIV-positive women, respectively. Our findings re-
flect that HIV-infected women are more likely predisposed to
other STIs. The higher incidence of STIs among HIV positive
women in our study is reflective of higher behavioral risk in this
cohort. These findings are consistent with other studies that re-
ported similar trends in behavioral risk among other high-risk pop-
ulation groups.17–19 HIV-infected individuals were more likely to
report unprotected sex than their HIV-uninfected counterparts.
The high incidence of STIs 3 months postpartum also sug-
gests that women in this study setting resume unprotected sexualTABLE 3. Incidence of STIs in HIV-Positive and HIV-Negative Women P
STI
HIV-Positive Women,
Incidence Rate of STI
Per 100 Person-Years (n/py) 95% CI P
N. gonorrhoeae 15.6 (15/95.986) 8.75–25.77
T. vaginalis 32.9 (27/82.025) 21.69–47.89
C. trachomatis 25.6 (21/82.025) 15.85–39.14
Any STI 58.0 (36/62.022) 40.65–80.36
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other STIs in HIV-infected women has serious implications for
maternal and child health and certainly demands a comprehensive
risk reduction strategy similar to that proposed for HIV-uninfected
women. Sexually transmitted infections and other coinfections
through evoking mucosal inflammatory responses are known to
amplify HIV shedding in cervical fluids, which in turn could in-
crease risk of mother-to-child transmission of HIV and rapid
HIV disease progression in the mother.20–23
Our other significant finding that is consistent with several
previous studies is critically persuasive for South Africa and other
countries to reconsider their syndromic approach to managing STIs
in pregnancy, particularly in settings with a high HIV prevalence.
Treatment of symptomatic STIs, partner tracing, and advocacy
for consistent and correct use of condoms seem to be the most
affordable and feasible option in resource-limited countries. Our
findings and that of other recent studies, however, question the
validity of this approach based on the large proportion of
asymptomatic STIs prevalent in pregnant and other high-risk
population groups.15,24–27 When extrapolating our findings to all
primary health clinics using the syndromic approach to treating
STIs in women, it would appear that an estimated 50% of pregnant
women with 1 or more STIs and asymptomatic will go untreated
if the syndromic approach is applied. Postdelivery, an estimated
80% of the women who are asymptomatic but infected with 1 or
more STIs would be missed. High estrogen levels in pregnancy
are known to be associated with increased production of vaginal
discharge and women are often unable to distinguish between
abnormal discharge associated with STIs and normal pregnancy-
induced vaginal discharge. Although the specificity of the
syndromic approach is lower in pregnancy when compared with
postpregnancy, women with asymptomatic STIs are more likely
to be treated in pregnancy as compared with postpregnancy
because of the overreporting of “abnormal” vaginal discharge
during pregnancy.
Although our study provides compelling evidence for prompt
diagnosis of STIs in pregnancy, without POC tests, we have no other
feasible and affordable alternative to the syndromic management
approach. Although POC tests are being developed and validated,
the selective use of the Cepheid GeneXpert currently being usedostdelivery (14 Weeks)
HIV-Negative Women,
Incidence Rate of STI
er 100 Person Year (n/py) 95% CI
Incidence
Rate Ratio P
2.8 (5/178.145) 0.91–6.55 5.47 0.001
17.6 (29/164.452) 11.8–25.33 1.83 0.02
20.8 (32/153.847) 14.2–29.36 1.22 0.44
36.4 (48/131.830) 26.9–48.28 1.55 0.03
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Undetected, Incident STIs in Peripartum Womento detect tuberculosis in South Africa could be explored for high-
risk pregnant including women who are HIV infected.28–30
We could also improve our existing prevention, diagnostic, and
treatment strategy for STI management. We would recommend
the following to be practiced at multiple visits between registration
for antenatal care and postdelivery: (i) client-centered risk reduction
counseling, (ii) history taking and an extensive personal interview
to determine sexual risk and establish signs and symptoms of an
STI, (iii) an uninterrupted supply of good quality condoms for
correct and consistent use, (iv) more effort at partner notification
and referral for treatment, and most importantly (v) repeat screening
using the syndromic approach in the third trimester of pregnancy or
before delivery and again at 3 months postdelivery.
Our study is not without limitations. Our 80% retention at
the 14-week postdelivery visit could selectively exclude women
at high risk, hence providing an underestimate of the STI inci-
dence. Although all women with a laboratory diagnosis of STIs
were treated within 2 to 3 weeks or at the next antenatal visit, we
did not adjust for these variabilities and treatment adherence when
calculating STI incidence at 14 weeks postdelivery.REFERENCES
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